GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pardes Biosciences Inc (NAS:PRDS) » Definitions » Price-to-Owner-Earnings

Pardes Biosciences (Pardes Biosciences) Price-to-Owner-Earnings : (As of May. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pardes Biosciences Price-to-Owner-Earnings?

As of today (2024-05-27), Pardes Biosciences's share price is $2.16. Pardes Biosciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Pardes Biosciences's Price-to-Owner-Earnings or its related term are showing as below:


PRDS's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.14
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-27), Pardes Biosciences's share price is $2.16. Pardes Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.29. Therefore, Pardes Biosciences's PE Ratio for today is At Loss.

As of today (2024-05-27), Pardes Biosciences's share price is $2.16. Pardes Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.29. Therefore, Pardes Biosciences's PE Ratio without NRI for today is At Loss.


Pardes Biosciences Price-to-Owner-Earnings Historical Data

The historical data trend for Pardes Biosciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pardes Biosciences Price-to-Owner-Earnings Chart

Pardes Biosciences Annual Data
Trend Dec20 Dec21 Dec22
Price-to-Owner-Earnings
- - -

Pardes Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pardes Biosciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Pardes Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pardes Biosciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pardes Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Pardes Biosciences's Price-to-Owner-Earnings falls into.



Pardes Biosciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Pardes Biosciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.16/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pardes Biosciences  (NAS:PRDS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Pardes Biosciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Pardes Biosciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Pardes Biosciences (Pardes Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
2173 Salk Avenue, Suite 250, PMB No. 052, Carlsbad, CA, USA, 92008
Pardes Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel oral-antiviral therapeutics to improve the lives of patients suffering from life-threatening disease, starting with the lead product candidate, pomotrelvir (formerly known as PBI-0451), which is in clinical development and intended to treat COVID-19 in adult and pediatric patients. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pomotrelvir inhibits the main coronaviral cysteine protease, a viral protein essential for the replication of all known coronaviruses, including SARS-CoV-2.
Executives
Fs Development Holdings Ii, Llc 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Opportunity Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Sean P. Brusky officer: Chief Commercial Officer C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Thomas G Wiggans director, officer: Chief Executive Officer
Foresite Capital Management V, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Pottage John C Jr director ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Alsup Laurie Smaldone director 190 WOOSAMONSA RD, PENNINGTON NJ 08534
Heidi Henson officer: Chief Financial Officer 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
J Jay Lobell director 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Brian Philippe Tinmouth officer: Chief Business & Strategy Ofcr 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Brian Kearney officer: Chief Development Officer C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Lee D Arnold officer: Chief Scientific Officer C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Uri A Lopatin director, officer: President and CEO C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013

Pardes Biosciences (Pardes Biosciences) Headlines

From GuruFocus

RM LAW Announces Investigation of Pardes Biosciences, Inc.

By PRNewswire PRNewswire 01-31-2023

Pardes Biosciences to Present at SVB Securities Global Biopharma Conference

By Stock market mentor Stock market mentor 02-01-2023